In a report published Thursday, JP Morgan analyst Geoff Meacham upgraded Biogen Idec Inc. BIIB from Neutral to Overweight and raised the price target from $300.00 to $375.00.
Meacham emphasized that Biogen's pipeline opportunities and MS survey implies an upside to shares. The analyst commented, “With respect to the MS franchise, we conducted a survey of 50 neurologists that points to upside for Tecfidera. Indeed, we have also fine tuned our MS estimates and are above consensus for Tecfidera, which is the key near-term commercial driver.”
Shares of Biogen Idec closed at $308.81. The stock is currently up 2 percent in Thursday's premarket trading.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in